Shattuck Labs (STTK) Other Non Operating Income (2019 - 2026)
Shattuck Labs (STTK) posted quarterly Other Non Operating Income of -$1000.0 for Q1 2026, up 50.0% year-over-year from -$666.67 in Q1 2025, and up 99.95% quarter-over-quarter from -$1.9 million in Q4 2025.
Shattuck Labs (STTK) Other Non Operating Income (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has reported Other Non Operating Income for 8 consecutive years, with -$1000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 50.0% year-over-year to -$1000.0; the TTM figure through Mar 2026 stood at -$692000.0 (up 55.61% YoY), while the FY2025 annual figure was -$4000.0, up 76.47% from the prior year.
- Other Non Operating Income rose to -$1000.0 in Q1 2026 per STTK's latest filing, from -$1.9 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $1.5 million in Q1 2024 and bottomed at -$4.2 million in Q4 2024.
- Historically, Other Non Operating Income has averaged -$54647.1 across 5 years, with a median of $574000.0 in 2025.
- On a YoY basis, Other Non Operating Income climbed as much as 388.15% in 2023 and fell as far as 368.36% in 2023.
- Shattuck Labs' Other Non Operating Income stood at -$727000.0 in 2022, then sank by 368.36% to -$3.4 million in 2023, then fell by 23.7% to -$4.2 million in 2024, then jumped by 54.3% to -$1.9 million in 2025, then soared by 99.95% to -$1000.0 in 2026.
- Business Quant data shows STTK's Other Non Operating Income at -$1000.0 in Q1 2026, -$1.9 million in Q4 2025, and $660000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Shattuck Labs | 962.96 Mn | 962.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26,000.00 |
| Mar 31, 2026 | -1,000.00 |
| Dec 31, 2025 | -1.93 Mn |
| Sep 30, 2025 | 660,000.00 |
| Jun 30, 2025 | 574,000.00 |
| Mar 31, 2025 | -2,000.00 |
| Dec 31, 2024 | -4.21 Mn |
| Sep 30, 2024 | 1.25 Mn |
| Jun 30, 2024 | 1.41 Mn |
| Mar 31, 2024 | 1.54 Mn |
| Dec 31, 2023 | -3.41 Mn |
| Sep 30, 2023 | 1.06 Mn |
| Jun 30, 2023 | 1.40 Mn |
| Mar 31, 2023 | 937,000.00 |
| Dec 31, 2022 | -727,000.00 |
| Sep 30, 2022 | 594,000.00 |
| Jun 30, 2022 | 287,000.00 |
| Mar 31, 2022 | -362,000.00 |
| Dec 31, 2021 | -2.02 Mn |
| Sep 30, 2021 | 170,000.00 |